Clinical Trials & Research News Weekly Roundup | Australian Researcher: Triple Therapy (Ivermectin, Zinc, Doxycycline) for COVID-19

Aug 17, 2020 | Digital Media, Video, Weekly Roundup

TrialSite News Weekly Roundup
Well-Respected Australian Researcher: Consider Triple Therapy (#Ivermectin, Zinc, #Doxycycline) for COVID-19: Thomas Borody touts FDA and Australian food and drug authority TGA approved Ivermectin, which he reports to use regularly in his hospital as it evidences positive results for #COVID19 and should be used immediately to fight the pandemic. The developer of the world’s first cure for peptic ulcers, which saved millions of lives worldwide, employed the same methodology to come up with the Ivermectin triple therapy. With over 30 formal clinical trials, many dozens of observational real-world initiatives and hundreds to possibly thousands of doctors already using the medicine, a particular momentum gains speed for additional randomized controlled trials and, just as importantly, a more serious dialogue about the potential of this approach for pragmatic and economical treatment options for COVID-19. https://www.trialsitenews.com/well-respected-australian-researcher-consider-triple-therapy-ivermectin-zinc-doxycycline-for-covid-19/  
 
TrialSite News Documentary: TrialSite have produced a documentary on this very topic in South America and will be releasing it to the public by this Friday. In this TrialSite production out of Peru we take an objective probe into the situation in Peru: how did Ivermectin become approved as a drug targeting COVID-19? What data was used as evidence to validate such a decision? Has consensus been met there on the approval or is there debate? https://youtu.be/vzO_9TX5vXc
 
RLF-100 (Aviptadil) Associated with Rapid Respiratory Failure Recovery Among COVID-19 Patients: Last week we touched on this subject of RLF-100 and this week, we’ll continue to expand on this story. NeuroRX, Inc. and Relief Therapeutics Holdings AG announced that the investigational therapy RLF-100 (Aviptadil) showed evidence of rapid recovery from respiratory failure in the most critically ill patients with COVID-19. In parallel, an independent group of researchers have reported that Aviptadil blocked replication of SARS-CoV-2 in human lung cells and monocytes. The drug has been granted Fast Track designation by FDA and is being developed as a Material Threat Medical Countermeasure in cooperation with the National Institutes of Health and other federal agencies. https://www.trialsitenews.com/rlf-100-aviptadil-associated-with-rapid-respiratory-failure-recovery-among-covid-19-patients/
 
Russia’s Gamaleya Vaccine Approved by Russian Health Authorities: The Russian Health Ministry has approved the world’s first COVID-19 vaccine after fewer than two months of formal human clinical trials. TrialSite News has been following the Gamaleya National Research Institute of Epidemiology and Microbiology (Gamaleya Institute) vaccine effort, and it is suspected that the Russians introduced some form of intensive human challenge trial that started with scientists and perhaps military personnel and then included broader groups, even an elite “VIP” group cohort. Now Russia’s President, Vladimir Putin, proudly declared to all via a televised video conference call with government ministers: “This morning, for the first time in the word, a vaccine against the new coronavirus was registered” in Russia. Putin, in anticipation of the critics, emphatically declared, “I would like to repeat that it has passed all the necessary tests.” https://www.trialsitenews.com/gamaleya-vaccine-approved-in-unprecedented-race-to-approved-vaccine-did-russia-win/
 
The Need for Convalescent Plasma in TN: Research is proving convalescent plasma can help those that have COVID-19 recover faster. However, Ballad Health is having to outsource plasma from other regions due to a lack in local donations, but one Northeast Tennessee native is making the most of an unfortunate situation. https://www.trialsitenews.com/the-need-for-convalescent-plasma-in-tn/

3 Comments

  1. Ron carson

    Thank you for providing much needed, non-politicized information. We really need this right now. Keep up the great work !

    • TrialSite

      Thanks Ron,
      We are grateful for the feedback. We are working to produce a lot more so we can drive a more healthy market.
      Thanks again and glad you visited.
      Publisher

  2. Hoyt Nelson

    Prof. Borody:

    * Has no background in covid-19 or #ivermectin
    * Has not written one relevant paper
    * Has not done one relevant study
    * Has not treated one patient with his triple therapy
    * Has not fully defined his therapy, esp. dosages are unspecified
    * Has meager evidence of his therapy’s efficacy
    * His trial won’t be done until 2023

    To his credit, he gets most of the facts right in his interviews, aside from implying that HE did the research when he says “WE did this in Bangladesh and WE did this in the US” — when in actuality he has not had a hand in ANY ivermectin research.

    Here is what Prof. Borody HAS done:

    * Read OTHER researchers’ ivermectin vs covid-19 papers
    * Took the Bangladesh protocol of ivermectin and doxycycline and threw in zinc
    * Named it “triple therapy”
    * Helped organize a clinical trial to test his therapy (a very good thing)
    * Did interviews on TV shows

    I’m glad that he has brought a lot of interest to ivermectin.

    I’m not happy that he has oversold the unknown efficacy of his triple therapy (“100% cured!”) and delivered the message that HE IS CERTAIN so well that people watch his videos and conclude that we can use his therapy IMMEDIATELY, so we can end the lockdown and go to school in a few weeks.

    I can’t manage to get through the videos in their entirety so I’m not positive, but I would bet $$$ that Prof. Brorody does NOT say with suitable scientist modesty:

    > Of course, we have to do a clinical study before we’ll know whether my triple therapy actually works — and that study won’t be done until 2023.

    I’m 99.99% sure he doesn’t mention the 2023 completion date, because people who watch his videos certainly don’t seem to be aware of it.

    Prof. Borody may well be right: his triple therapy is promising. Of course, he has to do a clinical study before we’ll know whether his triple therapy actually words — so we’ll patiently wait until January 2023, or later if the trial runs late as seem typical.

    By 2023 the study will probably be moot, because we’ll have good vaccines by then.

    The research may pay off, though, if covid-23 comes to town.

    Caveats:

    I said Prof. Borody has no background in covid-19 or ivermectin. I established that by searching PubMed and getting zero hits. It’s possible that he DID write a paper and I didn’t find it because I didn’t search the preprint servers. I doubt that, though, because he would have mentioned it if he wrote a study on the subject.

    I said Prof. Borody has never treated a patient with his therapy because HE said that during an interview. I suspect that he has never treated ANY covid-19 patient, period — but he never said that. I think he would have mentioned it, though, if he HAD treated a covid-19 patient.

Pin It on Pinterest